Intradermal vaccination for rabies prophylaxis: Conceptualization, evolution, present status and future

Expert Review of Vaccines

Volumn 13, Issue 5, 2014, Pages 641-655

  Madhusudana, Shampur Narayan ^a   Mani, Reeta Subramaniam ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

Rabies vaccines

Indexed keywords

RABIES VACCINE;

DRUG COST; IMMUNE RESPONSE; INFECTION PREVENTION; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RABIES; REVIEW; VACCINATION; ANIMAL; CELLULAR IMMUNITY; DRUG EFFECTS; FORECASTING; HUMAN; IMMUNIZATION; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; PROCEDURES; TRENDS;

ANIMALS; FORECASTING; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION SCHEDULE; INJECTIONS, INTRADERMAL; RABIES; RABIES VACCINES; VACCINATION;

EID: 84921293509     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2014.901893     Document Type: Review

References (102)

1. World Health Organization. WHO Expert Consultation on Rabies. Second report. World Health Organ Tech Rep Ser 2013;982:1-139
2. Knobel DL, Cleaveland S, Coleman PG, et al. Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ 2005;83(5):360-8
3. Wiktor TJ, Koprowski H. Successful immunization of primates with rabies vaccine prepared in human diploid cell strain WI-38. Proc Soc Exp Biol Med 1965;118:1069-73
4. World Health Organization. WHO Expert Consultation on rabies. First Report. World Health Organ Tech Rep Ser 2005;931:1-88
5. Vlassopoulos D, Arvanitis D, Lilis D, et al. Complete success of ID vaccination againsthepatitis B in advanced chronic renal failure and hemodialysis patients. Ren Fail 1997;19(3):455-60
6. Waite NM, Thomson LG, Goldstein MB. Successful vaccination with ID hepatitis B vaccine in hemodialysis patients previously nonresponsive to intramuscular hepatitis B vaccine. J Am Soc Nephrol 1995;5(11): 1930-4
7. Hoon Han S, Hee Woo J, Weber F, et al. Immunogenicity and safety of Intanza(-)/IDflu(-) ID influenza vaccine in South Korean adults: A multicenter, randomized trial. Hum Vaccin Immunother 2013;9(9): 1971-7
8. Scheifele DW, McNeil SA, Ward BJ, et al. Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: Results of a randomized, controlled comparison. Hum Vaccin Immunother 2013;9:11
9. Teunissen MB, Haniffa M, Collin MP. Insight into the immunobiology of human skin and functional specialization of skin dendritic cell subsets to innovate ID vaccination design. Curr Top Microbiol Immunol 2012;351:25-76
10. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449(7161):419-26
11. Teunissen MBM. Langerhans cells and other skin dendritic cells. In: Bos JD, editors. Skin immune system-cutaneous immunology and clinical immunodermatology. 3rd edition. CRC Press; Boca Raton, FL, USA: 2005
12. Flacher V, Bouschbacher M, Verronèse E, et al. Human Langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria. J Immunol 2006;177(11):7959-67
13. Nicolas JF, Guy B. ID, epidermal and transcutaneous vaccination: From immunology to clinical practice. Expert Rev Vaccines 2008;7(8):1201-14
14. Lambert PH, Laurent PE. ID vaccine delivery:will new delivery systems transform vaccine administratioñ Vaccine 2008; 26(26):3197-208
15. Le Borgne M, Etchart N, Goubier A, et al. Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo. Immunity 2006;24(2):191-201
16. Allan RS, Waithman J, Bedoui S, et al. Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity 2006;25(1):153-62
17. Partidos CD. Delivering vaccines into the skin without needles and syringes. Expert Rev Vaccines 2003;2(6):753-61
18. Nicholson KG, Prestage H, Cole PJ, et al. Multisite ID rabies vaccination. Immune response in man and protection of rabbits against death from street virus by post exposure administration of human diploid cell strain rabies vaccine. Lancet 1981; 2(8252):915-18
19. Bernard KW, Roberts MA, Sumner J, et al. Human diploid cell rabies vaccine. Effectiveness of immunization with small ID or subcutaneous doses. JAMA 1982;247(8): 1138-42
20. Burridge MJ, Baer GM, Sumner JW, Sussamu O. ID immunization with human diploid cell rabies vaccine. Serological and clinical response of persons with and without prior vaccination with duck embryo vaccine. J Am Med Assoc 1982;248(13): 1611-14
21. Burridge MJ, Sumner JW, Baer GM. ID immunization with human diploid cell rabies vaccine: Serological and clinical responses of immunized persons to ID booster vaccination. Am J Public Health 1984;74(5):503-5
22. Bernard KW, Mallonee J, Wright JC, et al. Preexposure immunization with ID human diploid cell rabies vaccine. Risks and benefits of primary and booster vaccination. JAMA 1987;257(8):1059-63
23. Warell MJ, Warell DA, Suntharsamai P, et al. An economical regimen of human diploid cell strain rabies vaccine for post-exposure prophylaxis. Lancet 1983; 2(8345):301-4
24. Warrell MJ, Suntharasamai P, Nicholson KG, et al. Multi-site ID and multi-site subcutaneous rabies vaccination: Improved economical regimens. Lancet 1984;1(8382):874-6
25. Haverson G, Wasi C. Use of post exposure ID rabies vaccination in a rural mission hospital. Lancet 1984;2(8398):313-15
26. Warrell MJ, Nicholson KG, Warrell DA, et al. Economical multiple-site ID immunisation with human diploid-cell-strain vaccine is effective for post-exposure rabies prophylaxis. Lancet 1985;1(8437):1059-62
27. Madhusudana SN, Saha SM, Sood M, Saxena SN. Multisite ID vaccination with tissue culture vaccine as an economical prophylactic regimen against rabies. Indian J Med Res 1988;87:1-4
28. Phanuphak P, Khawplod P, Sirivichayakul S, et al. Humoral and cell-mediated immune responses to various economical regimens of purified Vero cell rabies vaccine. Asian Pac J Allergy Immunol 1987;5(1):33-7
29. Chutivongse S, Wilde H, Supich C, et al. Post exposure prophylaxis for rabies with antiserum and ID vaccination. Lancet 1990; 335(8694):896-8
30. Madhusudana SN, Anand NP, Shamsundar R. Evaluation of two ID vaccination regimens using purified chick embryo cell vaccine for post-exposure prophylaxis of rabies. Natl Med J India 2001;14(3):145-7
31. WHO Expert Committee on Rabies. Eighth report. WHO Technical Report Series, No. 824. World Health Organization; Geneva, Switzerland: 1992
32. World Health Organization. World Health Organization recommendations on rabies post-exposure treatment and the correct technique of ID immunization against rabies. WHO/EMC/ZOO96.6. World Health Organization; Geneva, Switzerland: 1996
33. Quiambao BP, Dimaano EM, Ambas C, et al. Reducing the cost of post-exposure rabies prophylaxis: Efficacy of 0.1 ml PCEC rabies vaccine administered IDly using the Thai Red Cross post-exposure regimen in patients severely exposed to laboratory-confirmed rabid animals. Vaccine 2005;23(14):1709-14
34. Madhusudana SN, Sanjay TV, Mahendra BJ, et al. Comparison of safety and immunogenicity of purified chick embryo cell rabies vaccine (PCECV) and purified vero cell rabies vaccine (PVRV) using the Thai Red Cross ID regimen at a dose of 0.1 ml. Hum Vaccin 2006;2(5): 200-4
35. Briggs DJ, Banzhoff A, Nicolay U, et al. Antibody response of patients after postexposure rabies vaccination with small ID doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. Bull World Health Organ 2000;78(5):693-8
36. Khawplod P, Wilde H, Sirikwin S, et al. Revision of the Thai Red Cross ID rabies post-exposure regimen by eliminating the 90-day booster injection. Vaccine 2006; 24(16):3084-6
37. Narayana DH, Shampur MN, Sampath G, et al. Safety and immunogenicity study of a new purified chick embryo cell rabies vaccine Vaxirab-N (Pitman Moore strain) manufactured in India. Hum Vaccin Immunother 2013;10:1
38. Human and dog rabies prevention and control, report of the WHO/Bill Melinda Gates Foundation Consultation, 2009, Annecy, France, WHO/HTM/NTD/NZD 2010.1. World Health Organization, Geneva, Switzerland; 2010
39. Hickling JK, Jones KR, Friede M, et al. ID delivery of vaccines: Potential benefits and current challenges. Bull World Health Organ 2011;89(3):221-6
40. Sudarshan MK, Mahendra BJ, Madhusudana SN, et al. Assessing the relationship between antigenicity and immunogenicity of human rabies vaccines: Results of a metaanalysis. Hum Vaccin 2005;1:187-90
41. Sudarshan MK, Gangaboraiah B, Ravish HS, Narayana DH. Assessing the relationship between antigenicity and immunogenicity of human rabies vaccines when administered by ID route: Results of a metaanalysis. Hum Vaccin 2010;6(7):562-5
42. Beran J, Honegr K, Banzhoff A, Malerczyk C. Potency requirements of rabies vaccines administered IDly using the Thai Red Cross regimen: Investigation of the immunogenicity of serially diluted purified chick embryo cell rabies vaccine. Vaccine 2005;23(30):3902-7
43. Warrell MJ, Riddell A, Yu LM, et al. A simplified 4-site economical ID post-exposure rabies vaccine regimen: A randomised controlled comparison with standard methods. PLoS Negl Trop Dis 2008;2(4):e224
44. Mathew T. From guidelines to ground reality: Maximizing the benefits of IDRV in the fourth year of its implementation. Indian J Public Health 2012;56(3):187-8
45. Operational Guidelines for Rabies Prophylaxis and Intra-dermal Rabies Vaccination in Kerala. Available from: Http://rabies.org.in/rabies/wp-content/ uploads/2009/11/Operational-Guidelinesfor-Rabies-Prophylaxis-And-Intra-Dermal- Rabies-Vaccination-in-Kerala.pdf
46. Appraisal on implementation of intradermal rabies vaccination [IDRV] in India-The Kerala experience. Available from: Www. rabiesinasia.org/keralareport. pdf
47. Rabies; 2012. Available from: Www.gov.uk/government/uploads/system/ uploads/attachment-data/file/85762/Green-Book-Chapter-27-v3-0.pdf
48. Centers for Disease Control and Prevention. Available from: Http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectiousdiseases- related-To-Travel/perspectives-IDrabies-preexposure-immunization
49. Bernard KW, Fishbein DB, Miller KD, et al. Pre-exposure rabies immunization with human diploid cell vaccine: Decreased antibody responses in persons immunized in developing countries. Am J Trop Med Hyg 1985;34(3):633-47
50. Rosa FW. Pre-exposure prophylaxis in Peace Corps volunteers with ID human diploid cell rabies vaccine. J Trop Med Hyg 1983; 86(2):81-4
51. Madhusudana SN, Mani R, Ashwin YB, Desai A. Rabid fox bites and human rabies in a village community in southern India: Epidemiological and laboratory investigations, management and follow-up. Vector Borne Zoonotic Dis 2013;13(5): 324-9
52. Shantavasinkul P, Tantawichien T, Wacharapluesadee S, et al. Failure of rabies postexposure prophylaxis in patients presenting with unusual manifestations. Clin Infect Dis 2010;50(1):77-9
53. Wilde H. Failures of post-exposure rabies prophylaxis. Vaccine 2005;25(44):7605-9
54. John BM, Patnaik SK. Fatal rabies despite appropriate post-exposure prophylaxis. Indian Pediatr 2005;42(8):839-40
55. Hemachudha T, Mitrabhakdi E, Wilde H, et al. Additional reports of failure to respond to treatment after rabies exposure in Thailand. Clin Infect Dis 1999;28(1): 143-4
56. Bahmanyar M, Fayaz A, Nour-Salehi S, et al. Successful protection of humans exposed to rabies infection. Postexposure treatment with the new human diploid cell rabies vaccine and antirabies serum. JAMA 1976;236(24):2751-4
57. CDC. Human rabies prevention-United States, 1999. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999;48(RR-1):1-21
58. Ambrozaitis A, Laiskonis A, Balciuniene L, et al. Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site ID schedule (4-0-2-0-1-1): An immunogenic, cost-effective and practical regimen. Vaccine 2006;24(19):4116-21
59. Mahendra BJ, Harish BR, Vinay M. A study of factors influencing compliance to IDRV at anti-rabies clinic of Mandya Institute of Medical Sciences, Mandya. APCRI Journal 2009;11:18-20
60. Jesha M, Martin J, Bina T, Lailabi RL. Jayadev. Compliance to IDRV at the anti rabies clinic in a tertiary care hospital in North Kerala. APCRI Journal 2011;12:21-4
61. Sudarshan MK, Narayana DH, Madhusudana SN, et al. Evaluation of a one week ID regimen for rabies post-exposure prophylaxis: Results of a randomized, open label, active-controlled trial in healthy adult volunteers in India. Hum Vaccin Immunother 2012;8(8): 1077-81
62. Shantavasinkul P, Tantawichien T,Wilde H, et al. Postexposure rabies prophylaxis completed in 1 week: Preliminary study. Clin Infect Dis 2010;50(1):56-60
63. Comparison of PEP vaccination regimens including the proposed 4-site ID regimen reduced to a schedule with 3 clinic visits. Available from: Www.plosntds.org/attachments/pntd.0000982-Response-To-Warrell16Mar11.pdf
64. Roumiantzeff M, Ajjan N, Vincent-Falquet JC. Experience with preexposure rabies vaccination. Rev Infect Dis 1988;10(Suppl 4):S751-7
65. Sabchareon A, Chantavanich P, Pasuralertsakul S, et al. Persistence of antibodies in children after ID or intramuscular administration of preexposure primary and booster immunizations with purified Vero cell rabies vaccine. Pediatr Infect Dis J 1998;17(11):1001-7
66. Lang J, Hoa DQ, Gioi NV, et al. Immunogenicity and safety of low-dose ID rabies vaccination given during an Expanded Programme on immunization session in Viet Nam: Results of a comparative randomized trial. Trans R Soc Trop Med Hyg 1999;93(2):208-13
67. Vien NC, Feroldi E, Lang J. Long-Term anti-rabies antibody persistence following intramuscular or low-dose ID vaccination of young Vietnamese children. Trans R Soc Trop Med Hyg 2008;102(3):294-6
68. Pengsaa K, Limkittikul K, Sabchareon A, et al. A three-year clinical study on immunogenicity, safety, and booster response of purified chick embryo cell rabies vaccine administered intramuscularly or IDly to 12-To 18-month-old Thai children, concomitantly with Japanese encephalitis vaccine. Pediatr Infect Dis J 2009;28(4): 335-7
69. Kamoltham T, Thinyounyong W, Phongchamnaphai P, et al. Pre-exposure rabies vaccination using purified chick embryo cell rabies vaccine IDly is immunogenic and safe. J Pediatr 2007; 151(2):173-7
70. Kamoltham T, Thinyounyong W, Khawplod P, et al. Immunogenicity of Simulated PCECV Postexposure Booster Doses 1, 3, and 5 Years after 2-Dose and 3-Dose Primary Rabies Vaccination in Schoolchildren. Adv Prev Med 2011;2011:403201
71. Jaijaroensup W, Limusanno S, Khawplod P, et al. Immunogenicity of rabies postexposure booster injections in subjects who had previously received ID preexposure vaccination. J Travel Med 1999;6(4):234-7
72. Dreesen DW, Fishbein DB, Kemp DT, Brown J. Two-year comparative trial on the immunogenicity and adverse effects of purified chick embryo cell rabies vaccine for pre-exposure immunization. Vaccine 1989; 7(5):397-400
73. Nicholson KG, Farrow PR, Bijok U, Barth R. Pre-exposure studies with purified chick embryo cell culture rabies vaccine and human diploid cell vaccine: Serological and clinical responses in man. Vaccine 1987; 5(3):208-10
74. Jentes ES, Blanton JD, Johnson KJ, et al. The global availability of rabies immune globulin and rabies vaccine in clinics providing direct care to travelers. J Travel Med 2013;20(3):148-58
75. Khawplod P, Jaijaroensup W, Sawangvaree A, et al. One clinic visit for pre-exposure rabies vaccination (a preliminary one year study). Vaccine 2012;30(19):2918-20
76. Pancharoen C, Thisyakorn U, Tantawichien T, et al. Failure of pre and post exposure rabies vaccination in a child infected with HIV. Scand J Infect Dis 2001;33(5):390-1
77. Thisyakorn U, Pancharoen C, Ruxrungtham K, et al. Safety and immunogenicity of preexposure rabies vaccination in children infected with human immunodeficiency virus type 1. Clin Infect Dis 2000;30(1):218
78. Rabies vaccines: WHO position paper. Wkly Epidemiol Rec 2010;85:309-20
79. Sudarshan MK, Madhusudana SN, Mahendra BJ, et al. Boosting effect of purified chick embryo cell rabies vaccine using the ID route in persons previously immunized by the intramuscular route or vice versa. Natl Med J India 2006;19(4): 192-4
80. Rabies vaccines. WHO position paper. Wkly Epidemiol Rec 2007;82(49-50): 425-35
81. Khawplod P, Wilde H, Tantawichien T, et al. Potency, sterility and immunogenicity of rabies tissue culture vaccine after reconstitution and refrigerated storage for 1 week. Vaccine 2002;20(17-18):2240-2
82. Goswami A, Plun-Favreau J, Nicoloyannis N, et al. The real cost of rabies post-exposure treatments. Vaccine 2005;23(23):2970-6
83. Suntharasamai P, Warrell MJ, Viravan C, et al. Purified chick embryo cell rabies vaccine: Economical multisite ID regimen for post-exposure prophylaxis. Epidemiol Infect 1987;99(3):755-65
84. Chutivongse S, Supich C, Wilde H. Acceptability and efficacy of purified vero-cell rabies vaccine in Thai children exposed to rabies. Asia Pac J Public Health 1988;2(3):179-84
85. Phanuphak P, Khaoplod P, Benjavongkulchai M, et al What happens if ID injections of rabies vaccine are partially or entirely injected subcutaneously? Bull World Health Organ 1990;68(1):83-5
86. Kopel E, Oren G, Sidi Y, David D. Inadequate antibody response to rabies vaccine in immunocompromised patient. Emerg Infect Dis 2012;18(9):1493-5
87. Tantawichien T, Jaijaroensup W, Khawplod P, Sitprija V. Failure of multiple-site ID postexposure rabies vaccination in patients with human immunodeficiency virus with low CD4+ T lymphocyte counts. Clin Infect Dis 2001;33:E122-4
88. Taylor DN, Wasi C, Bernard K. Chloroquine prophylaxis associated with a poor antibody response to human diploid cell rabies vaccine. Lancet 1984;1(8391): 1405
89. Pappaioanou M, Fishbein DB, Dreesen DW, et al. Antibody response to preexposure human diploid-cell rabies vaccine given concurrently with chloroquine. N Engl J Med 1986;314(5):280-4
90. Jaijaroensup W, Tantawichien T, Khawplod P, et al. Postexposure rabies vaccination in patients infected with human immunodeficiency virus. Clin Infect Dis 1999;28(4):913-14
91. Sirikwin S, Likanonsakusl S, Wardywinyoo S, et al. Antibody response to eight site ID rabies vaccination in patients infected with human immunodeficiency virus. Vaccine 2009;27(32):4350-4
92. WHO. Safety of Injections: Global facts and figures (WHO/EHT/04/04). WHO; Geneva, Switzerland: 2004
93. Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK. Microneedle-based vaccines. Curr Top Microbiol Immunol 2009;333: 369-93
94. Ansaldi F, de Florentiis D, Durando P, Icardi G. Fluzone(-) ID vaccine: A promising new chance to increase the acceptability of influenza vaccination in adults. Expert Rev Vaccines 2012;11(1): 17-25
95. Laurent PE, Bourhy H, Fantino M, et al. Safety and efficacy of novel dermal and epidermal microneedle delivery systems for rabies vaccination in healthy adults. Vaccine 2010;28(36):5850-6
96. Bins AD, Jorritsma A, Wolkers MC, et al. A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med 2005;11(8): 899-904
97. Kim YC, Prausnitz MR. Enabling skin vaccination using new delivery technologies. Drug Deliv Transl Res 2011;1(1):7-12
98. Mohammed AJ, AlAwaidy S, Bawikar S, et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med 2010;362(25):2351-9
99. Icardi G, Orsi A, Ceravolo A, Ansaldi F. Current evidence on ID influenza vaccines administered by SoluviaTM licensed micro injection system. Hum Vaccin Immunother 2012;8(1):67-75
100. Wongsaroj P, Udomchaisakul P, Tepsumethanon S, et al. Rabies neutralizing antibody after 2 ID doses on days 0 and 21 for pre-exposure prophylaxis. Vaccine 2013;31(13):1748-51
101. Mills DJ, Lau CL, Fearnley EJ, Weinstein P. The immunogenicity of a modified ID pre-exposure rabies vaccination schedule-A case series of 420 travelers. J Travel Med 2011;18(5):327-32
102. Lau CL, Hohl N. Immunogenicity of a modified ID pre-exposure rabies vaccination schedule using a purified chick embryo cell vaccine: An observational study. Travel Med Infect Dis 2013;11(6):427-30